Clinical trials: Pancreatic Cancer Stage
Metastatic Pancreatic Cancer
Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer
This trial is a single arm open-label, phase II aiming to assess the clinical activity of niraparib in chemotherapy-naïve biomarker-selected pancreatic cancer patients.
- Trial name
- PARPi-PANC (NCT05442749)
- Testing
- Niraparib
- Where
- 4 sites in France
- Volunteers
- 2 people
- Sponsor
- Centre Leon Berard
Gastrinoma, Glucagonoma
Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
This phase II trial studies regorafenib in treating patients with neuroendocrine tumors that have spread from the primary site (place where it started) to other places in the body.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT02259725
- Testing
- regorafenib, laboratory biomarker analysis
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- University of Southern California
Breast Cancer, Colorectal Cancer
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
RATIONALE: Sorafenib and pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of tumor cells by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00703638
- Testing
- cisplatin, pemetrexed disodium, sorafenib
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Peritoneal Carcinomatosis, Ovarian Cancer Stage IIIB
PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer
The PIPAC nab-pac study is designed to examine the maximal tolerated dose of albumin bound nanoparticle paclitaxel (nab-pac, Abraxane) administered with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC), in a…
- Conditions
- Peritoneal Carcinomatosis, Ovarian Cancer Stage IIIB, Ovarian Cancer Stage IIIC, Ovarian Cancer Stage IV
- Trial name
- PIPAC-nabpac (NCT03304210)
- Testing
- PIPAC with Abraxane
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- University Hospital, Ghent
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
This phase II trial studies how well giving selumetinib and erlotinib hydrochloride together works in treating patients with locally advanced or metastatic pancreatic cancer that is refractory to chemotherapy.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT01222689
- Testing
- erlotinib hydrochloride, selumetinib, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Borderline Resectable Pancreatic Cancer
Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer
This is a prospective, single-arm, phase II study to evaluate the efficacy and safety of irinotecan liposome II in combination with oxaliplatin and 5-FU/LV in perioperative treatment of borderline resectable pancreatic cancer in…
- Trial name
- undetermined (NCT06387810)
- Testing
- irinotecan liposome II combined with 5-FU/LV and oxaliplatin
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Peking Union Medical College Hospital
Respiratory Tract Neoplasms, Thymic Neoplasms
High Dose Somatostatin Analogues in Neuroendocrine Tumors
Octreotide (OCT) is a somatostatin analogue (SSA) available in a long-acting formulation, conventionally administered every 28 days at the maximum dose of 30 mg.
- Conditions
- Respiratory Tract Neoplasms, Thymic Neoplasms, Pancreatic Neoplasms, Gastrointestinal Neoplasms
- Trial name
- HIDONET (NCT00990535)
- Testing
- Octreotide-LAR
- Where
- Italy
- Volunteers
- 28 people
- Sponsor
- Federico II University
Pancreatic Ductal Adenocarcinoma
MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma
This research study is being conducted to determine the effects of PEGPH20 plus chemotherapy treatment on the MRI characteristics of locally advanced pancreatic cancer patient tumors.
- Trial name
- NCT04134468
- Testing
- Pegvorhyaluronidase alfa, Abraxane, Gemcitabine
- Where
- United States
- Sponsor
- Abramson Cancer Center at Penn Medicine
Metastatic Pancreatic Cancer
Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer
The purpose of this study is to evaluate the safety and clinical activity of plerixafor in combination with cemiplimab in patients with metastatic pancreatic cancer.
- Trial name
- NCT04177810
- Testing
- Cemiplimab, Plerixafor
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cancer, Pancreas
Phase II Trial of Erlotinib in Advanced Pancreatic Cancer
This is an open-label, multi-center phase II study of erlotinib in patients with metastatic or locally advanced, unresectable pancreatic cancer who have received up to one line of gemcitabine based chemotherapy.
- Trial name
- NCT00497224
- Testing
- Erlotinib
- Where
- 5 sites in Canada
- Volunteers
- 51 people
- Sponsor
- University Health Network, Toronto
Metastatic Pancreatic Cancer
A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen
This is a single arm, open label Phase II clinical trial to evaluate the efficacy and safety of donafenib combined with S-1 in treating Patients with metastatic pancreatic cancer after chemotherapy with Nab-paclitaxel plus…
- Trial name
- NCT05138159
- Testing
- Donafenib, S1
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Fudan University
Pancreatic Cancer
Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00376948
- Testing
- genistein, erlotinib hydrochloride, gemcitabine hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
This phase II trial is studying how well saracatinib works in treating patients with previously treated metastatic pancreatic cancer.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT00735917
- Testing
- saracatinib, pharmacogenomic studies, pharmacological study
- Where
- 9 sites in United States, Australia and 1 more
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
A Phase II Study of Locally Advanced Pancreatic Cancer
The primary end point is to evaluate the 9-month progression free survival rate and safety profile after FOLFIRINOX versus GOFL induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic…
- Trial name
- NCT01867892
- Testing
- ICT of oxapliplatin, irinotecan, leucovorin, and fluorouracil and CCRT, ICT of Gemcitabine,oxapliplatin, leucovorin, and fluorouracil + CCRT
- Volunteers
- 86 people
- Sponsor
- National Health Research Institutes, Taiwan
Pancreatic Cancer
Gem-TABS in Unresectable Pancreatic Carcinoma
The purpose of this study is to: Find out the largest dose of sodium bicarbonate that can be given with gemcitabine. Determine if the combination of sodium bicarbonate and gemcitabine produces better control of pancreatic cancer…
- Trial name
- NCT01198821
- Testing
- Sodium bicarbonate (g/kg/day), Gemcitabine (mg/m²)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Pancreatic Cancer
Safety/Efficacy Study of Rexin-G to Treat Pancreatic Cancer
The goal of the adaptive trial design is to determine the over-all safety of escalating doses of Rexin-G and to determine the optimal dosing regimen for Rexin-G that would document the significant clinical benefits required to…
- Trial name
- NCT00504998
- Testing
- Rexin-G
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Epeius Biotechnologies
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations
This phase II trial studies whether adding pembrolizumab to olaparib (standard of care) works better than olaparib alone in treating patients with pancreatic cancer with germline BRCA1 or BRCA2 mutations that has spread to other…
- Trial name
- NCT04548752
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 533 sites in United States
- Volunteers
- 68 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00268411
- Testing
- gemcitabine hydrochloride, oxaliplatin
- Where
- 15 sites in France
- Volunteers
- 80 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Pancreatic Cancer
UCN-01 and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer
RATIONALE: UCN-01 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00045747
- Testing
- 7-hydroxystaurosporine, fluorouracil
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Solid Tumor, Non-Small-Cell Lung Cancer
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS.
- Conditions
- Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
- Trial name
- NCT07094204
- Testing
- ASP5834, panitumumab
- Where
- 22 sites in United States, France and 3 more
- Volunteers
- 404 people
- Sponsor
- Astellas Pharma Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.